SNIBE(SZ:300832) Xin Lang Cai Jing·2025-08-27 10:52Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in its financial performance and potential impacts from market conditions [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 2.185 billion, a year-on-year decrease of 1.18% - The net profit attributable to shareholders was 771 million, down 14.62% year-on-year - The net profit excluding non-recurring items was 726 million, a decline of 16.33% year-on-year - In Q2 2025, revenue was 1.060 billion, a decrease of 10.88% year-on-year - The net profit attributable to shareholders in Q2 was 334 million, down 30.06% year-on-year - The net profit excluding non-recurring items in Q2 was 309 million, a decline of 34.00% year-on-year [1][2]. Cost and Expense Analysis - The gross profit margin in Q2 2025 was 68.89%, a decrease of 2.67 percentage points year-on-year, primarily due to a decline in the gross margin of instrument products - The sales expense ratio was 19.82%, an increase of 5.14 percentage points year-on-year - The management expense ratio was 2.92%, an increase of 0.54 percentage points year-on-year [2]. Research and Development - The company increased its R&D investment, with R&D expenses in Q2 2025 amounting to 135 million, representing 12.76% of revenue - The company made progress in product registrations, obtaining several registration certificates for testing kits and a new flagship instrument model, MAGLUMI X10, which enhances testing efficiency [2]. Market Expansion - As of June 2025, the company served 1,835 tertiary hospitals in China, achieving a coverage rate of 47.60%, with a coverage rate of 63.51% for top-tier hospitals - In H1 2025, overseas revenue reached 952 million, a year-on-year increase of 19.57% - The company established operational systems in 14 core countries, driving regional business growth [3]. Profit Forecast and Valuation - The company revised its net profit forecasts for 2025-2027 to 1.876 billion, 2.206 billion, and 2.598 billion, reflecting decreases of 5.8%, 9.8%, and 11.4% respectively from previous estimates - The current price corresponds to a PE ratio of 24, 21, and 17 for 2025-2027 - The company is positioned as a leading player in the domestic chemiluminescence market and is expected to benefit from import substitution and overseas expansion [3].